Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Current status of blood and marrow transplantation for patients with AML

Bone Marrow Transplantation volume 42, pages S14–S17 (2008)Cite this article

Abstract

During the past decade it has become apparent that patients can be transplanted successfully after preparation with regimens of reduced intensity. Reduced intensity preparations have resulted in lower morbidity and mortality during the pre-engraftment period, but have not reduced later occurring infections, GVHD and relapse. Outcome-determining risk factors that characterize patients at diagnosis as well as during their course include age, cytogenetic configuration, hematopoietic elements and a previous history of myelodysplasia or cytoreductive therapy for a pre-existing malignancy. These factors are complemented by the response to induction therapy and subsequent treatments as well as by the duration of the response. More recently, gene expression profiling of leukemic cells has added a new dimension to simultaneously assessed biological risk factors that may ultimately lead to individuation of therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Thomas ED, Buckner CD, Clift RA, Fefer A, Johnson FL, Neiman PE et al. Marrow transplantation for acute nonlymphoblastic leukemia. NEJM 1979; 301: 507–508.

    Google Scholar 

  2. Sandmaier BM, Mackinnon S, Richard W, Childs RW . Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant 2007; 13: 87–97.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Heuser M, Wingen LU, Steinemann D, Cario G, von Neuhoff N, Tauscher M et al. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologica 2005; 90: 1484–1492.

    CAS  PubMed  Google Scholar 

  4. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analyses of 1612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  5. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Coopearative Oncology Group Study. Blood 2000; 96: 4075–4083.

    CAS  PubMed  Google Scholar 

  6. Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W, Haferlach T . The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 2004; 89: 1082–1090.

    PubMed  Google Scholar 

  7. Baldus CD, Mrozek K, Marcucci G, Bloomfield CD . Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise report. Br J Haematol 2007; 137: 387–400.

    Article  CAS  PubMed  Google Scholar 

  8. Marucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2007; 25: 3337–3343.

    Article  Google Scholar 

  9. Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE . FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007; 110: 1262–1270.

    Article  CAS  PubMed  Google Scholar 

  10. Gale RP, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995; 16: 203–208.

    CAS  PubMed  Google Scholar 

  11. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D et al. Karyotype in acute myeloblastic leukemia: prognostic significance for Bone Marrow Transplantation in first remission: a European Group for Blood and Marrow Transplantation Study. Blood 1997; 90: 2931–2938.

    CAS  PubMed  Google Scholar 

  12. Fung HC, Stein A, Slovak ML, O'Donnell MR, Snyder DS, Cohen S et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003; 9: 766–771.

    Article  CAS  PubMed  Google Scholar 

  13. Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007; 13: 655–664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 2002; 8: 435–443.

    Article  PubMed  Google Scholar 

  15. Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007; 110: 409–417.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trail. Blood 2003; 102: 1232–1240.

    Article  CAS  PubMed  Google Scholar 

  17. Yanada M, Matsuo K, Emi N, Naoe T . Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a meta analysis. Cancer 2005; 103: 1652–1658.

    PubMed  Google Scholar 

  18. Cook G, Clark RE, Crawley C, Mackinnon S, Russell N, Thomson K et al. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy. Biol Blood Marrow Transplant 2006; 12: 293–300.

    Article  PubMed  Google Scholar 

  19. Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE et al. Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose Etoposide and Cyclophosphamide. Biol Blood Marrow Transplant 2006; 12: 480–489.

    Article  CAS  PubMed  Google Scholar 

  20. Breems DA, van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonk LF et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 1969–1978.

    Article  PubMed  Google Scholar 

  21. Bertz H, Potthoff K, Finke J . Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21: 1480–1484.

    Article  PubMed  Google Scholar 

  22. Spyridonidis A, Bertz H, Ihorts G, Grüllich C, Finke J . Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (⩾60 years) with active myeloid malignancies. Blood 2005; 105: 4147–4148.

    Article  CAS  PubMed  Google Scholar 

  23. Krauter J, Heil G, Hoelzer D, Ottmann O, Martin H, Lübbert M et al. Role of consolidation therapy in the treatment of patients up to 60 years with high risk AML. Blood 2005; 106: 172 (abstract).

    Google Scholar 

  24. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110: 2744–2748.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous Busulfan and Thymoglobulin. Biol Blood Marrow Transplant 2007; 13: 814–821.

    Article  CAS  PubMed  Google Scholar 

  26. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007; 21: 2540–2544.

    Article  CAS  PubMed  Google Scholar 

  27. Schmid C, Labopin M, Nagler A, Bomhauser M, Finke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 31: 4938–4945.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada

    H A Messner

Authors
  1. H A Messner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H A Messner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Messner, H. Current status of blood and marrow transplantation for patients with AML. Bone Marrow Transplant 42 (Suppl 1), S14–S17 (2008). https://doi.org/10.1038/bmt.2008.106

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.106

Keywords

This article is cited by

Search

Advanced search

Quick links